Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2004

View Archived Issues

Nudix hydrolases show promise as antibiotic targets in tuberculosis

Cel-Sci reviews recent progress

Bavarian Nordic and GlaxoSmithKline in global Imvamune collaboration

First phase III study of GVAX prostate cancer vaccine commences enrollment

Phase II results for INKP-102

Completion of financing round at Acuity

Therapeutic benefits of mitoxantrone in multiple sclerosis

Acamprosate does not affect alcohol pharmacokinetics and pharmacodynamics

Telomerase inhibitor inhibits glioblastoma growth in vivo

LY-411575 tested in novel animal model of Alzheimer's

Novel therapeutic polyagent for Alzheimer's disease therapy

Aeolus name change completed

FDA extends review period for low-dose Yasmin NDA

European approval for Teveten Plus

AOP Orphan obtains Thromboreductin registrations in Central Europe

First phase II monotherapy study of 17-AAG begins

Novavax to reacquire rights to Estrasorb from King

Diversa signs agreement with GSK to advance novel antiinfective

Lower resistance to NNRTIs found with nevirapine plus Combivir in HIV-infected mothers

Low incidence of resistance to PIs found in HIV-infected patients treated with lopinavir/ritonavir

Novel cell penetrating peptides inhibit HIV-1 replication

Promising vitamin D analogue for the treatment of psoriasis

Antiinflammatory effects of PDE4 inhibitors on airways epithelial cell functions

Novel PARP inhibitors for the treatment of cerebral infarction

Sankyo isolates new antibacterial agents

Yamanouchi reports VEGF inhibitors for angiogenesis-related disorders

HIV integrase inhibitors described by Japan Tobacco

ProSkelia claims vitronectin receptor antagonists

Fujisawa discloses selective cyclooxygenase-1 inhibitors

Transdermal lidocaine for the treatment of neuropathic sensory loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...